Adaptimmune Therapeutics plc (ADAPY)

Market Cap	1.62M -97.8%
Revenue (ttm)	65.09M -54.0%
Net Income	-169.76M
EPS	-0.66
Shares Out	265.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,084
Open	0.0060
Previous Close	0.0090
Day's Range	0.0055 - 0.0061
52-Week Range	0.0001 - 0.3578
Beta	1.89
Analysts	n/a
Price Target	n/a
Earnings Date	May 26, 2026

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company al...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 506
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADAPY

Financial Performance

In 2024, Adaptimmune Therapeutics's revenue was $178.03 million, an increase of 195.34% compared to the previous year's $60.28 million. Losses were -$70.81 million, -37.81% less than in 2023.